OTIC Stock Overview
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.28|
|52 Week High||US$2.59|
|52 Week Low||US$0.24|
|1 Month Change||-32.07%|
|3 Month Change||-87.34%|
|1 Year Change||-85.64%|
|3 Year Change||-88.35%|
|5 Year Change||-91.81%|
|Change since IPO||-98.38%|
Recent News & Updates
Otonomy crashes 73% as mid-stage trial for tinnitus candidate fails
The shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.
Otonomy GAAP EPS of -$0.19 beats by $0.01
Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.
|OTIC||US Pharmaceuticals||US Market|
Return vs Industry: OTIC underperformed the US Pharmaceuticals industry which returned 2.9% over the past year.
Return vs Market: OTIC underperformed the US Market which returned -23% over the past year.
|OTIC Average Weekly Movement||29.3%|
|Pharmaceuticals Industry Average Movement||11.3%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: OTIC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 29% a week.
Volatility Over Time: OTIC's weekly volatility has increased from 17% to 29% over the past year.
About the Company
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss.
Otonomy Fundamentals Summary
|OTIC fundamental statistics|
Is OTIC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OTIC income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.93|
|Net Profit Margin||0.00%|
How did OTIC perform over the long term?See historical performance and comparison
Is OTIC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OTIC?
Other financial metrics that can be useful for relative valuation.
|What is OTIC's n/a Ratio?|
Price to Book Ratio vs Peers
How does OTIC's PB Ratio compare to its peers?
|OTIC PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
MJNE MJ Holdings
ONTX Onconova Therapeutics
COCP Cocrystal Pharma
ADMP Adamis Pharmaceuticals
Price-To-Book vs Peers: OTIC is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (3.5x).
Price to Earnings Ratio vs Industry
How does OTIC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: OTIC is good value based on its Price-To-Book Ratio (0.5x) compared to the US Pharmaceuticals industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is OTIC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate OTIC's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of OTIC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OTIC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OTIC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Otonomy forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OTIC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OTIC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OTIC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OTIC is forecast to have no revenue next year.
High Growth Revenue: OTIC is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OTIC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Otonomy performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OTIC is currently unprofitable.
Growing Profit Margin: OTIC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OTIC is unprofitable, but has reduced losses over the past 5 years at a rate of 14.8% per year.
Accelerating Growth: Unable to compare OTIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OTIC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: OTIC has a negative Return on Equity (-165.51%), as it is currently unprofitable.
Discover strong past performing companies
How is Otonomy's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OTIC's short term assets ($56.3M) exceed its short term liabilities ($11.7M).
Long Term Liabilities: OTIC's short term assets ($56.3M) exceed its long term liabilities ($27.0M).
Debt to Equity History and Analysis
Debt Level: OTIC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if OTIC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OTIC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OTIC has less than a year of cash runway if free cash flow continues to grow at historical rates of 17.3% each year.
Discover healthy companies
What is Otonomy current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Otonomy Dividend Yield vs Market|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (Otonomy)||n/a|
Notable Dividend: Unable to evaluate OTIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OTIC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OTIC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OTIC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OTIC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Weber (62 yo)
Dr. David Allen Weber, Ph D., has been the Chief Executive Officer and President of Otonomy, Inc. since November 2010. Dr. Weber has been Non-Executive Director at Oculis ehf since September 2018.Dr. Webe...
CEO Compensation Analysis
|David Weber's Compensation vs Otonomy Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$3m||US$600k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$3m||US$568k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$2m||US$546k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$5m||US$546k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$2m||US$530k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$3m||US$515k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$800k||US$500k|
Compensation vs Market: David's total compensation ($USD3.42M) is above average for companies of similar size in the US market ($USD780.01K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
Experienced Management: OTIC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: OTIC's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|28 Mar 22||SellUS$46,295||David Weber||Individual||19,269||US$2.41|
|28 Mar 22||SellUS$23,159||Paul Cayer||Individual||9,639||US$2.41|
|28 Mar 22||SellUS$13,692||Robert Savel||Individual||5,699||US$2.41|
|28 Mar 22||SellUS$10,538||Alan Foster||Individual||4,386||US$2.41|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Otonomy, Inc.'s employee growth, exchange listings and data sources
- Name: Otonomy, Inc.
- Ticker: OTIC
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$15.872m
- Shares outstanding: 56.99m
- Website: https://www.otonomy.com
Number of Employees
- Otonomy, Inc.
- 4796 Executive Drive
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OTIC||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 2014|
|7OT||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2014|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/26 00:00|
|End of Day Share Price||2022/09/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.